| In Vitro |
Fusarochromanone (FC101; 10 μM; 24 hours) induces apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines[1]. Fusarochromanone (FC101; 0-1 μM; 24 h) induces the cleavage of both caspase-3 and PARP, a well-known substrate for activated caspases. FC101 does not affect the expression of the anti-apoptotic proteins, Bcl-2, Bcl-XL, Mcl-1, or the pro-apoptotic proteins BAD, BAK, BAX[1]. Fusarochromanone (FC101) exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from 10 nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive. Cell Cycle Analysis[1] Cell Line: HaCat and P9-WT cell lines Concentration: 10 μM Incubation Time: 24 hours Result: Showed cells in the G2 and M phases of the cell cycle for both cell lines. Western Blot Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 0.05 μM, 0.1 μM, 0.2 μM, 0.5 μM, 1 μM Incubation Time: 24 hours Result: Induced the cleavage of both caspase-3 and PARP.
|
